Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Apellis Pharmaceuticals, Inc. is seeking a Senior Product Manager for US HCP Marketing to shape and drive multichannel promotional campaigns. You will work with cross-functional teams to translate brand strategies into tangible marketing initiatives that engage healthcare professionals.
You will lead partnerships with agencies, manage budgets, and develop measurement plans to optimize impact across digital and field channels while aligning with regulatory and compliance requirements.
Opportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases. Summary: The US Senior Product Manager, HCP Marketing will play a key role in the development and execution of healthcare professional (HCP) marketing strategies, omnichannel engagement campaigns, and promotional initiatives. This individual will work closely with the US HCP Marketing Director to ensure initiatives are aligned with brand strategy and business objectives. The role requires strong cross-functional collaboration, strategic thinking, and the ability to independently lead assigned projects from planning through execution.
Hybrid
Willing to travel domestically up to 30% of the time and attend events outside of business hours (e.g., occasional weekends and evenings).
Base salary for this role will consider multiple factors, including but not limited to, candidate qualifications, relevant expertise, specialized skills, and industry experience in complement-targeted therapies. The targeted base salary range for this position is $147,000-$197,000. This range represents the base salary only and reflects Apellis' commitment to competitive compensation within the biopharmaceutical industry. The final salary offered may vary based on individual qualifications, business needs, and current market conditions.
Apellis offers a comprehensive benefits package, including a 401(k) plan with company match, inclusive family building benefits, flexible time off, summer and winter shutdowns, paid family leave, disability and life insurance, and more!
Please note that as of May 14th, Biogen Inc. has acquired Apellis Pharmaceuticals.
Apellis is an equal opportunity employer and complies with all applicable federal, state and local fair employment practices laws. Apellis strictly prohibits and does not tolerate discrimination against employees, applicants or any other covered persons because of race, color, religion, creed, national origin or ancestry, ethnicity, sex (including pregnancy), gender (including gender nonconformity and status as a transgender or transsexual individual), age, physical or mental disability, citizenship, past, current or prospective service in the uniformed services, genetic information, marital status, AIDS/HIV status, smoker/nonsmoker, and occupational pneumoconiosis or any other characteristic protected under applicable federal, state or local law. For San Francisco postings: Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records. Other Duties: Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.